Pharmaceuticals, Biotechnology and Life Sciences
Yellow Wood Partners will buy the Dr. Scholl’s foot care business from Bayer for a purchase price of $585 million, the companies said amid Bayer’s voluntarily recall of a product in the USA.
Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level, the company said Monday in a statement.
Novartis said Tuesday that the USFDA marked its investigational sickle cell drug crizanlizumab for Priority Review, which could be the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease.
Arbutus Biopharma’s AB-506 is a potent oral capsid inhibitor, preliminary results from testing have shown, the company said Monday.
Gerresheimer AG has had a successful second quarter, en route to meeting all of its targets for 2019, Dietmar Siemssen, the CEO, has said in a press release Tursday.
Taris Bio has dosed the first patient in a test of its investigational product TAR-200 combined with Bristol-Myers Squibb’s Opdivo.
Biomarck Pharmaceuticals has improved the Overall Response Rate (ORR) in the BIO-11006/SOC group compared to standard of care alone at 3 months in the Phase 2 study in NSCLC, which compares standard of care alone, to SOC plus BIO-11006 in 60 patients with stage 4.
Trovagene has started erolling patients for its second phase study of onvansertib plus FOLFIRI and Avastin (bevacizumab) for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation.
Neovacs has received a first payment of a total amount up to €702.000, for its preclinical development program AllergyVacs, within the grant awarded by the National Agency for Research (ANR), conducted in collaboration with Inserm and the Immunology and Allergy Department of Pasteur Institute.
Glenmark Pharmaceuticals got the final approval by the US FDA for its Ranolazine Extended-Release Tablets, generic version of Gilead’s Ranexa.